MK-6482-011 An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L

NCT04586231

An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Associated Conditions

Kidney Cancer

Principal Investigator

Sponsor

MK-6482-011 Merck Study Team

This trial is being done to test MK-6482 + lenvatinib in people with a type of kidney cancer called advanced clear cell Renal Cell Carcinoma (ccRCC). MK-6482 is still being researched and has not been approved to use alone or with other drugs to treat advanced ccRCC. Lenvatinib has been approved to treat different types of cancer including some types of kidney cancer. It has not been approved to use with MK-6482 to treat advanced ccRCC. The use of MK-6482 + levantinib in this trial is experimental. This trial will compare MK-6482 + lenvatinib to cabozantinib, which is a standard approved treatment for ccRCC.

This study is currently enrolling.